All Articles

With CEO Steven Pelton’s immediate departure, Aegis Brands faces a critical juncture. Can an interim committee stabilize the ship amid declining revenues?

Merck's new HIV drug, IDVYNSO™, gets a crucial boost via a public health deal, signaling a strategic play to reclaim ground in a multi-billion dollar market.

Ring Energy's entry into the Russell 3000 is more than a milestone; it's a testament to strategic discipline. What does this reveal about value creation?

Bullish secures key approval in Gibraltar for tokenized securities, a strategic move paired with its Equiniti acquisition to build a regulated, end-to-end digital asset ecosystem.

XPENG's new X-Mind framework moves beyond reactive systems, enabling vehicles to simulate the future and make safer, more human-like driving decisions.

Larimar Therapeutics is rewriting the rare disease playbook. Its BLA filing for nomlabofusp leverages a novel FDA-aligned endpoint, creating a de-risked path to market.

The insurer's new app aims to unify fragmented health records. Is this the future of member engagement, or another data privacy tightrope for consumers?

Beyond the hype, Eisai's latest data on at-home Alzheimer's treatment and a new anti-tau drug signals a seismic shift in patient care and market strategy.

BPCL's new joint venture with Shell and Tiki Tar isn't just a deal—it's a strategic move to dominate India's high-value infrastructure materials market.

Generalist marketing is failing fintech. As complexity and regulation rise, a new class of specialized agency emerges to bridge the gap to predictable revenue.

Despite a 24% income dip from lower oil prices, Mexco Energy’s debt-free strategy, rising gas output, and robust royalty income reveal a resilient playbook.

A new filtration system promises to turn industrial wastewater into a resource, tackling disposal costs, water scarcity, and even creating drinking water.

After a 45-year silence, Idaho's notorious Bunker Hill Mine is shipping metal again. This isn't just a mine restart; it's a high-stakes test of modern tech, ESG finance, and America's bid for resource independence.

A new report finds workers overwhelmingly turn to voice for urgent tasks, revealing a deep communication crisis for frontline staff and a new role for AI.

WideTrial's innovative program hit a major milestone, providing 200 ALS patients with an investigational drug and creating a new model for compassionate use.

Chandigarh University's global summit, drawing top scientists, reveals India's strategic plan to dominate the global education market via its National Education Policy.

Digital signage firm Creative Realities plans a public offering to fund growth and fortify its balance sheet. Is this a signal of strength or a necessary risk?

Viridian's Lumvoa gains FDA approval for Thyroid Eye Disease, challenging a blockbuster drug and validating DRI Healthcare's unique royalty investment model.

For the third year, Schneider Electric is TIME's most sustainable company. We look beyond the accolade at the strategy and real-world impact driving its success.

Comcast's plan to split its media and tech arms is more than a corporate shuffle; it's a stark admission that the age of the all-in-one conglomerate is over.